Dr. Mario Habek  
University Department of Neurology  
University Hospital Center Zagreb  
Kišpatićeva 12  
HR-10000 Zagreb  
Croatia

Re Manuscript # 1828

Please proofread the pages of your article which will appear in an upcoming issue of the Canadian Journal of Neurological Sciences. Check any figures and pictures carefully. Returning any changes: **OPTION #1:** Fax the sheets back to (403) 229-1661, as well as mailing them. Mail the original with any changes marked clearly in **RED** pen as occasionally *faxes do not read clearly*. **OPTION #2:** *Clearly spell out any changes and where they are located in an email.* If there are **NO** changes, an email may be sent stating that the article is **OK TO PROCEED TO PRINT AS IS**.

**Copy editor needs clarification on the following:**

- **For Your Information Re: Acronyms**
  All acronyms must be defined on *first appearance* in the article.
  Also our **Journal standards** state that a sentence **must not** start with an acronym.

These need to be returned to us within **72 hours**.

Yours sincerely,

Maggie McCallion  
Designer/Production Coordinator

URGENT  
10 September 2012
A 50-year-old, previously healthy woman presented with memory impairment and handwriting changes. Brain magnetic resonance imaging (MRI) showed hyperintense lesions in T2 and fluid-attenuated inversion recovery (FLAIR) sequences in the left thalamus (Figure 1A and B). Diffuse large B-cell lymphoma was found in a specimen obtained by stereotactic brain biopsy. There were no signs of extraneural lymphoma dissemination. A diagnosis of primary central nervous system (CNS) Large B-cell lymphoma (primary central nervous system lymphoma [PCNSL]) was made. The patient was treated with high-dose methotrexate and whole brain irradiation with completed resolution of clinical symptoms and radiological findings.

Two years later she developed headaches accompanied by dysgeusia, olfactory hallucinations and light-headedness. Brain MRI showed one hyperintense lesion of the right temporal lobe in T2 and FLAIR sequences with homogenous contrast enhancement surrounded with perifocal edema (Figure 1C and D) consistent with relapsed lymphoma. To confirm the relapse a brain biopsy was performed which showed findings consistent with acute disseminated encephalomyelitis (ADEM) (Figure 2). The patient was admitted to our department for further assessment. At that time her neurological examination was unremarkable and her symptoms ameliorated without receiving corticosteroid treatment. Also, the lesion in the right temporal lobe appeared significantly smaller and enhancement was not observed on repeated MRI. Cerebral spinal fluid (CSF) analysis showed 8 cells/mm³, predominately small lymphocytes; there were no oligoclonal IgG bands. Cytological and microbiological CSF analyses were unremarkable. Extensive work-up to exclude secondary demyelinating lesion was performed including immunological evaluation, HIV, hepatitis, Toxoplasma gondii, Treponema pallidum, Borrelia burgdorferi, EBV and CMV serology, angiotensin-converting enzyme and beta2-microglobulin levels. All findings were normal. She was diagnosed as having ADEM and not treated with corticosteroids. Follow-up MRIs, three and six months later, showed no lesions in the right temporal lobe. As well, cognitive evaluation on follow-up was normal. Twelve months later the patient is in remission without symptoms.

**DISCUSSION**

We describe a rare association of demyelinating lesion with histological characteristics of ADEM developing two years after PCNSL and suggest a term, reversed “sentinel”, for this association. Primary central nervous system lymphoma is a rare malignant tumor accounting for 4% of all intracranial neoplasms¹. Contrast-enhanced brain MRI is the standard neuroimaging method but, to distinguish PCNSL from other potential causes and make a definitive diagnosis, brain biopsy is required. The MRI features of newly diagnosed PCNSL have been described extensively, but there is only one paper describing MRI characteristics at relapse². Recurrence of PCNSL is suggested by newly developing enhancing parenchymal lesions detected by contrast-enhanced T1-weighted MRI. We describe a unique case where the neuroimaging findings suggested ADEM, which, after exclusion of other potential causes, was confirmed by brain biopsy. This case highlights the importance of considering PCNSL in the differential diagnosis of ADEM, especially in the setting of previously diagnosed lymphoma.
MRI-scan in comparison to previous scans, which was the case in our patient. Authors of this study have shown that parenchymal contrast enhancement is the most frequently found MRI sign in PCNSL relapse\(^2\). However, local recurrence at the site of the initial tumor presentation was only found in only 25% of patients, while in two out of 16 cases, recurrence appeared solely on the contralateral side without involvement of primary lymphoma location\(^2\). Despite this, PCNSL relapses are sometimes treated based on MRI findings, without histological proof.

Several case reports described demyelinating pseudotumoral lesions preceding PCNSL\(^3,4\). All of these, so called, ‘sentinel’ demyelinating lesions occurred prior to PCNSL and receded spontaneously or after corticosteroid treatment. However in many of these case reports patients received corticosteroids prior to biopsy that can make the histological diagnosis of lymphoma difficult\(^5\). As well perivascular lymphocytic cuffing may be seen in both primary CNS lymphoma and demyelinating lesions. In addition, PCNSL often shows many CD3-positive reactive T cells admixed with the atypical B cells. CD68-macrophages are also often found in the background of many CNS tumors or destructive processes. Despite of these similarities a spontaneous remission and long follow-up argue against PCNSL relapse. A unique feature of our case is the occurrence of demyelinating lesion two years after PCNSL treatment and its resolution without any treatment. We decided not to give any treatment to the patient because all symptoms resolved spontaneously after brain biopsy and there was a significant improvement in the follow-up MRIs.

Although ‘sentinel’ demyelinating lesion can precede PCNSL, little is known about the pathogenesis of this peculiar coexistence. Some authors speculated that a host immune response to lymphoma or common viral etiological background could potentially play a role in this ‘other way around’ scenario with demyelinating lesion appearing after PCNSL\(^4\). Newly developed lesions in PCNSL patients are primarily considered to be tumor recurrence but can also be caused by radiation-induced changes (early or delayed), delayed methotrexate neurotoxicity\(^6\), infection or demyelination.

In summary, discrimination between a demyelinating lesion and PCNSL in patients treated for PCNSL with newly developed neurological impairment may be challenging with clinical and imaging methods. Accurate diagnosis is crucial to avoid delayed treatment of recurrent malignant disease and unnecessary administration of toxic therapies, so clinicians should rely on brain biopsy to confirm suspected relapses.

Despite the favorable scenario in this case, high level of clinical and neuroradiological vigilance is warranted and every new brain lesion in PCNSL patients should be considered tumor recurrence until reliably proven otherwise.

**Author Contributions**

**Study concept and design:** Barun and Habek.

**Acquisition of data:** Barun, Kinda, Aurer, Žarković, Adamec and Habek.

**Analysis and interpretation of data:** Barun, Kinda, Aurer, Žarković, Adamec and Habek.

**Drafting of the manuscript:** Barun.

**Critical revision of the manuscript for important intellectual content:** Barun, Kinda, Aurer, Žarković, Adamec and Habek.

**Administrative, technical, and material support:** Barun, Kinda, Aurer, Žarković, Adamec and Habek.

**REFERENCES**